H3K27ac-induced lncRNA PAXIP1-AS1 exhibits oncogenic property in ovarian cancer by targeting miR-6744-5p/PCBP2 axis

We aimed to explore role of lncRNA PAX-interacting protein 1- antisense RNA1(PAXIP1-AS1) in ovarian cancer (OC). RT-qPCR analysis identied upregulation of PAXIP1-AS1 in OC cell lines. Functionally, PAXIP1-AS1 knockdown inhibited cell proliferation, accelerated cell apoptosis, and suppressed cell migration and epithelial-mesenchymal transition (EMT) process. Upregulation PAXIP1-AS1 was induced by CBP-mediated H3K27 acetylation (H3K27ac) via bioinformatic analysis and ChIP assay. Furthermore, PAXIP1-AS1 served as a competing endogenous RNA (ceRNA) to regulate PCBP2 expression by sponging microRNA-6744-5p (miR-6744-5p). Restoration experiments showed that overexpressed PCBP2 rescued effect of silenced PAXIP1-AS1 on cell proliferation, apoptosis, migration and EMT. Overall, lncRNA PAXIP1-AS1 activated by H3K27ac functioned as a tumor promoter in OC via mediating miR-6744-5p/PCBP2 axis, which provided promising insight into exploration on OC therapy.


Introduction
As a female gynecologic malignancy, ovarian cancer (OC) is one of the most common type of lethal tumors with higher mortality rate worldwide [1]. Each year, there is a continuous increase in the newlydiagnosed OC cases and in OC-related deaths [2]. In recent decades, therapeutic approaches, such as surgery, chemotherapy and radiotherapy, have achieved great progress. However, the long-term survival is still poor due to the imperceptible symptoms at early stage and the distant metastasis at advanced stage [3,4]. Thus, it is quite imperative to explore the underlying mechanisms and develop novel methods for the treatment of OC.
Long noncoding RNAs (lncRNAs), a new group of noncoding RNAs that over 200 nucleotides in length, are recently identi ed [5]. Although no potential ability in protein-coding, lncRNAs have been found to exert important effect on multiple biological processes [6,7]. Extensive studies have suggested that lncRNAs could modulate survival, cell proliferation, stemness, differentiation, and epithelial-mesenchymal transition (EMT) [8][9][10]. For example, lncRNA CRNDE shows a high level in tongue squamous cell carcinoma tissues and inhibits miR-384 to facilitate cell proliferation and metastasis [11]. Besides, highlyexpressed LINC01296 is revealed to predict poor prognosis in lung cancer patients and enhances tumor growth via modulating miR-598/Twist1 pathway [12]. Importantly, mounting reports indicated that lncRNAs regulate gene expression to mediate cancer progression through multiple ways, such as histone modi cation, transcriptional and post-transcriptional regulation [13]. Among which, lncRNAs was widely reported as competing endogenous RNA (ceRNA) that involved in lncRNA/miRNA/mRNA network [14].
This is a new model which proposes that lncRNAs regulate expression of target gene via miRNA response elements [15]. Because of the importance of lncRNAs in cancers, much more research should be conducted to depict their functions in OC.
LncRNA PAX-interacting protein 1-antisense RNA1 (PAXIP1-AS1) has been reported as a tumor promoter in glioma by aggravating cell invasion and angiogenesis [16]. However, its functional role in other cancers, especially in OC remains obscure. This study focused on the biological role and underlying mechanism of PAXIP1-AS1 in OC. The results demonstrated that PAXIP1-AS1 induced by H3K27ac was upregulated in OC cells and promoted cellular process in OC by sponging miR-6744-5p and targeting PCBP2, providing a new molecular mechanism implicated in OC cellular development.

Cell lines
Human ovarian epithelial cell line (HOSEpiC) and OC cell lines (SKOV3, A2780, OVCAR3 and COV362) were obtained from American Type Culture Collection (ATCC, Manassas). All above cell lines were cultured at 37 °C in RPMI-1640 medium with a supplement of 100 U/ml penicillin, 100 mg/ml streptomycin and 10% fetal bovine serum (FBS, Invitrogen, Carlsbad, CA) in a humidi ed atmosphere containing 5% CO 2 . C646, an inhibitor of acetylation, was commercially provided by Sigma Chemical (St. Louis, MO).

RT-qPCR
Firstly, Trizol reagent (Invitrogen) was used to isolate total RNAs from OC cell lines. Then, the reverse transcription of miRNA or lncRNA/mRNA was performed by miRNA First-Stand cDNA Synthesis Kit (GeneCopoeia) or cDNA Synthesis SuperMix Kit (TransGen, Beijing, China). Afterwards, RT-qPCR was performed on Applied Biosystems 7500 Real-time PCR Systems (Thermo Fisher Scienti c). Gene expression was quanti ed by 2 −ΔΔCt method normalized to U6 or GAPDH.

Colony formation assay
Cells at a density of 600 cells/well were grown in 6-well plates with RPMI-1640 medium containing 10% FBS. After culturing for two weeks, methanol was used for xing colonies for 15 min at room temperature, and then the cells were stained with 0.1% crystal violet (Invitrogen) for 15 min. Finally, number of visible colonies were manually counted.

EdU assay
Transfected cells of SKOV3 or OVCAR3 were collected and planted into 96-well plates at the density of 1 × 10 4 cells each well. Later, the plates were added with EdU assay kit (Ribobio) at 37 °C for 2 h. Cell nuclei was stained by DAPI solution. Finally, uorescence microscope (Olympus, Tokyo, Japan) was applied to observe proliferative cells.
Flow cytometry analysis SKOV3 or OVCAR3 cells were seeded in a 6-well plate. After centrifugalization, the binding buffer, resuspended with residue, was added with 5-μL Annexin V-FITC and 5-μL propidium (PI). Then, ow cytometer (BD, Franklin Lake, NJ, USA) was used to measure cell apoptotic rate, and results were analyzed by the software WinMDI 2.9 (Invitrogen).

Western blot analysis
Cell lysis was conducted in RIPA lysis buffer, and then the lysate was separated by 10% SDS-PAGE and transferred to PVDF membranes (Millipore). Blocked with 5% nonfat milk, the membranes were incubated with primary antibodies overnight at 4 °C. After an incubation with secondary antibody at 37 °C for 1 h, enhanced chemiluminescence (ECL) Plus kit (Beyotime, Shanghai, China) visualized the protein bands.

Transwell assay
The migration ability was assessed by the use of transwell chambers without matrigel. In brief, cells (1 × 10 5 ) were seeded into upper chambers contained 200ul serum-free media. The lower chambers were added with 600 ul of 20% FBS media. Incubated for 48 h, cells without invasion in the upper chambers were wiped away by cotton wool. Fixed with methanol, cells were stained with 0.5% crystal violet in the lower chamber. Lastly, ve random elds were photographed under an inverted microscope.

ChIP assay
ChIP assays were carried out by ChIP Assay Kit (Thermo Fisher Scienti c) with SKOV3 or OVCAR3 cells.
For DNA-protein cross-links, SKOV3 or OVCAR3 cells were incubated with 1% formaldehyde for 10 minutes, and then an ultrasound machine was utilized to break the cross-linked chromatin DNAs into segments sized 200 to 1000 bp. The chromatin lysate was precipitated by anti-H3K27ac (Abcam), anti-CBP (Abcam) or anti-IgG (Abcam). Finally, RT-qPCR analyzed the ChIP samples.

Subcellular fractionation assay
Firstly, the nuclear and cytoplasmic fractions of SKOV3 and OVCAR3 cells were obtained. Then, with Cytoplasmic & Nuclear RNA Puri cation Kit (Norgen), the fractions were separated and puri ed as per the manual. At last, RT-qPCR analyzed the isolated RNA (GADPH, U6, PAXIP1-AS1). GAPDH was the internal control for cytoplasm, and the distribution of PAXIP1-AS1 in nucleus was normalized to U6.
RNA pull down assay NC-miRNA and miR-6744-5p-WT/Mut were labeled with biotin, and then transfected into SKOV3 and OVCAR3 cells. Streptavidin magnetic beads were used to incubate with the cell lysates for 4 h at 4 °C. Using precooled lysis buffer and salt buffer, the beads were rinsed. After that, PAXIP1-AS1 or PCBP2 level was detected following the extraction of pull-down RNAs.

RIP assay
For RNA immunoprecipitation, EZMagna RIP kit (Millipore) was applied. Cells were lysed in RIP lysis buffer after being harvested. Then, the cell lysate was incubated with magnetic beads absorbed anti-IgG (Millipore) or anti-Ago2 antibody (Millipore). Finally, RT-qPCR analyzed the puri ed RNA.

Statistical analysis
Three biological repeats were applied to all experimental procedures. Shown as the mean ± SD, data were statistically analyzed through GraphPad Prism 6 (GraphPad). Differences between two groups were analyzed by Student's t test or one-way ANOVA for multiple groups with P < 0.05 as cut-off value.

Results
Upregulated PAXIP1-AS1 in OC enhanced cell proliferation, migration and inhibited cell apoptosis First, PAXIP1-AS1 expression pattern in OC cells was assessed by RT-qPCR for the investigation of its biological role. Compared with HOSEpiC cell line, high expression of PAXIP1-AS1 was observed in OC cell lines (SKOV3, A2780, OVCAR3 and COV362) ( Figure 1A). Then, SKOV3 and OVCAR3 cells presenting higher PAXIP1-AS1 expression were chose to probe functional role of PAXIP1-AS1 in OC. Accordingly, we designed and conducted loss-of-function assays by transfecting sh-PAXIP1-AS1 (sh-PAXIP1-AS1#1/2) into SKOV3 and OVCAR3 cells. The results of RT-qPCR analysis con rmed that PAXIP1-AS1 expression was apparently downregulated after sh-PAXIP1-AS1 transfection ( Figure 1B). Through colony formation assay, we found silenced PAXIP1-AS1 signi cantly decreased colonies of SKOV3 and OVCAR3 cells ( Figure 1C). EdU assay further con rmed the inhibitive effect of PAXIP1-AS1 de ciency on cell proliferation ( Figure 1D). In addition, ow cytometry analysis suggested that cell apoptosis was remarkably promoted by sh-PAXIP1-AS1 transfection ( Figure 1E). To further con rm this, levels of apoptosis-related proteins after PAXIP1-AS1 knockdown was tested by western blot analysis. The results showed that silenced PAXIP1-AS1 reduced Bcl-2 expression and lifted Bax, caspase 3 and caspase 9 levels ( Figure 1F). Transwell assay denoted that PAXIP1-AS1 knockdown obviously lessened migrated cells ( Figure 1G). Moreover, expressions of migration-related proteins (MMP2, MMP9) and EMT-relevant proteins (E-cadherin, N-cadherin) with sh-PAXIP1-AS1 transfection was testi ed. As we observed, MMP2, MMP9 and N-cadherin protein levels were decreased while E-cadherin protein level was induced by PAXIP1-AS1 silencing ( Figure 1H). Taken together, PAXIP1-AS1 was upregulated in OC and exhibited oncogenic role by facilitating cell proliferation, migration, EMT and suppressing cell apoptosis.

PAXIP1-AS1 was transcriptionally activated by CBP-mediated H3K27ac
Thereafter, we explored the cause of PAXIP1-AS1 upregulation in OC. Existing reports highlighted that lncRNAs could be activated through H3K27ac at transcriptional level [17,18]. Afterwards, high density of H3K27ac enrichment was predicted in PAXIP1-AS1 promoter region through genome bioinformatics analysis (Figure 2A). To further validate this, ChIP assay was performed. As demonstrated in Figure 2B, PAXIP1-AS1 promoter region was enriched with H3K27ac in both OC cells and HOSEpiC cell line.
Importantly, H3K27ac enrichment level was signi cantly increased in SKOV3 and OVCAR3 cell lines with comparison of HOSEpiC cell line. Interestingly, we found that PAXIP1-AS1 expression was signi cantly downregulated when OC cells were treated C646, an inhibitor of histone acetyltransferase (HAT) ( Figure   2C). Thus, we wondered whether there were other vital enzymes involved in H3K27ac process. Previous studies have conformed that CBP is crucial for chromatin acetylation and responsible for the promotive acetylation [19]. To test this, RT-qPCR was used to evaluate CBP expression in OC cells. As expected, compared to HOSEpiC cell line, CBP was upregulated in OC cells ( Figure 2D). Subsequently, results of ChIP assay uncovered that CBP precipitates was obviously enriched by PAXIP1-AS1 promoter ( Figure 2E).

PAXIP1-AS1 regulated OC cellular process by upregulating PCBP2
At last, we probed whether PCBP2 was necessary for the regulation of PAXIP1-AS1 on cellular process in OC. First, we transfected pcDNA3.1/PCBP2 into SKOV3 and OVCAR3 cells to overexpress PCBP2 ( Figure   5A). Colony formation and EdU assays depicted that cell proliferation hampered by PAXIP1-AS1 knockdown was recovered by PCBP2 overexpression (Figure 5B-C). Moreover, the apoptosis of OC cells was promoted by PAXIP1-AS1 silencing, and such promotion was rescued by PCBP2 upregulation ( Figure  5D). Furthermore, overexpressed PCBP2 also reserved the effect of PAXIP1-AS1 knockdown on levels of apoptosis-relevant proteins ( Figure 5E). Transwell assay demonstrated that cell migration inhibited by silenced PAXIP1-AS1 was counteracted by pcDNA3.1/PCBP2 transfection ( Figure 5F). Additionally, the role of PAXIP1-AS1 downregulation in levels of proteins associated with migration and EMT process was countervailed via overexpressing PCBP2 ( Figure 5G). Conclusively, PAXIP1-AS1 accelerated OC cellular process through regulating PCBP2.

Discussion
Over the past decades, signi cant attention has been payed on the effect of dysregulated lncRNAs in the progression of cancers, including OC. Previous studies have identi ed numerous lncRNAs as tumor facilitator or suppressor in OC. For example, lncRNA FLVCR1-AS1 enhances cell migration and EMT process in OC through mediating miR-513/YAP1 axis [22]. LncRNA WDFY3-AS2 acts as a tumor suppressor to inhibit tumor growth in OC via delaying miR-18a [23]. LncRNA HAND2-AS1 represents antioncogenic property in OC by targeting BCL2L11 [24]. This study was to explore the function of PAXIP1-AS1 in OC. Previously, it has been stated that PAXIP1-AS1 was upregulated and served as an oncogenic lncRNA in glioma [16]. Herein, we found high expression level of PAXIP1-AS1 in OC cell lines. Functional assays revealed that PAXIP1-AS1 accelerated proliferation, restrained apoptosis, and promoted migration and EMT process in OC cells. This suggested that PAXIP1-AS1 played carcinogenic role in OC.
Histone H3 on lysine 27 acetylation (H3K27ac) has been known as a common type of histone posttranslational regulation, associating with active enhancer modulatory elements to transcriptionally activate gene expression [25,26]. Previous researches have suggested that H3K27ac at promoter regions led to the overexpression of some carcinogenic lncRNAs, such as PLAC2 and lnc-SLC4A1-1 [27,28], thus facilitating tumor development. Herein, we discovered high enrichment of H3K27ac at PAXIP1-AS1 promoter region via UCSC genome browser. Then, H3K27ac high level on the promoter region of PAXIP1-AS1 was validated through ChIP assay. The decreased PAXIP1-AS1 expression by HAT inhibitor (C646) further veri ed that PAXIP1-AS1 upregulation was attributed to H3K27ac modi cation. Previously, increasing evidence has implied that CBP is an essential regulator on histone acetylation and gene transcription, including lncRNA [19,27]. Thus, we rstly validated that CBP interacted with PAXIP1-AS1 promoter to trigger H3K27ac and upregulated PAXIP1-AS1 expression.
In mechanism, it was widely proved that lncRNAs play the role of ceRNAs by which lncRNAs released mRNAs from posttranscriptional silence through sponging miRNAs [20,29]. Our study rst found that miR-6744-5p could be potentially targeted by PAXIP1-AS1. Moreover, we conducted luciferase reporter assay and RNA pull down assay to con rm the strongest a nity of miR-6744-5p with PAXIP1-AS1.
Formerly, miR-6744-5p was reported to accelerate anoikis by directly targeting NAT1 enzyme in breast cancer [30]. Furthermore, we identi ed that PCBP2 was the target gene for miR-6744-5p. Former studies have showed the oncogenic role of PCBP2 in cancers. As reported, PCBP2 was involved in cell proliferation and migration in bladder cancer [31]. PCBP2 enhanced cell viability through regulating CDK2 in gastric cancer [32]. PCBP2 was overexpressed in glioblastoma and associated with unfavorable prognosis [33]. In our study, we rst found that miR-6744-5p combined with PCBP2 to repress its expression, and that PAXIP1-AS1 upregulated PCBP2 through miR-6744-5p. Rescue assay delineated that PAXIP1-AS1 aggravated cell growth and migration by targeting PCBP2 in OC.
In conclusion, our study rst depicted that H3K27ac-induced lncRNA PAXIP1-AS1 promoted cellular process through miR-6744-5p/PCBP2 axis, suggesting PAXIP1-AS1 as an underlying novel biomarker for improving research on OC molecular therapy.